SIL index, comprising stage, soluble interleukin‐2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B‐cell lymphoma

Rituximab (R) plus doxorubicin, cyclophosphamide, vincristine, and prednisolone (CHOP) chemotherapy (R‐CHOP) is widely accepted as standard care for diffuse large B‐cell lymphoma (DLBCL) patients. The revised International Prognostic Index (R‐IPI) was established in 2007 after the addition of rituxi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Tomita, Naoto, Sakai, Rika, Fujisawa, Shin, Fujimaki, Katsumichi, Taguchi, Jun, Hashimoto, Chizuko, Ogawa, Koji, Yamazaki, Etsuko, Ishigatsubo, Yoshiaki
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2012
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7659199/
https://ncbi.nlm.nih.gov/pubmed/22587388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2012.02331.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars